VENCLEXTA Drug Patent Profile

When do Venclexta patents expire, and when can generic versions of Venclexta launch?

Venclexta is a drug marketed by Abbvie and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and sixty-seven patent family members in forty-three countries.

The generic ingredient in VENCLEXTA is venetoclax. One supplier is listed for this compound. Additional details are available on the venetoclax profile page.

DrugPatentWatch^® Generic Entry Outlook for Venclexta

Venclexta was eligible for patent challenges on April 11, 2020.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 23, 2032. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for VENCLEXTA

International Patents:	267
US Patents:	10
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VENCLEXTA

Paragraph IV (Patent) Challenges for VENCLEXTA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VENCLEXTA	Tablets	venetoclax	10 mg, 50 mg and 100 mg	208573	2	2020-04-13

US Patents and Regulatory Information for VENCLEXTA

VENCLEXTA is protected by fourteen US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 11,369,599.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-003	Apr 11, 2016		RX	Yes	Yes	8,546,399		Y	Y
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-003	Apr 11, 2016		RX	Yes	Yes	9,174,982
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-003	Apr 11, 2016		RX	Yes	Yes

International Patents for VENCLEXTA

When does loss-of-exclusivity occur for VENCLEXTA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

European Patent Office

Guatemala

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

New Zealand

Norway

Peru

Philippines

Poland

Portugal

Russian Federation

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VENCLEXTA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2011332043
Brazil	112013012740
Canada	2817629

Supplementary Protection Certificates for VENCLEXTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3179991	122025000057	Germany		PRODUCT NAME: ACALABRUTINIB ODER EIN PHARMAZEUTISCH UNBEDENKLICHES SALZ DAVON, IN KOMBINATION MIT VENETOCLAX ODER EINEM PHARMAZEUTISCH UNBEDENKLICHEN SALZ DAVON, MIT ODER OHNE OBINUTUZUMAB; REGISTRATION NO/DATE: EU/1/20/1479 20250602
2435432	17C1018	France		PRODUCT NAME: VENETOCLAX; REGISTRATION NO/DATE: EU/1/16/1138 20161207
2435432	386 50008-2017	Slovakia		PRODUCT NAME: VENETOKLAX; REGISTRATION NO/DATE: EU/1/16/1138 20161207

Investment Scenario and Fundamentals Analysis for VENCLEXTA (Venetoclax)

Last updated: February 19, 2026

What is the current market position of VENCLEXTA?

VENCLEXTA (venetoclax) is a BCL-2 inhibitor marketed by AbbVie, indicated primarily for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), with recent approvals extending into other hematologic malignancies. Since its FDA approval in 2016 for CLL with 17p deletion, VENCLEXTA has gained significant market share, owing to its efficacy and favorable safety profile.

Market Penetration

• Global sales: Reached approximately $3.9 billion in 2022.
• Market share: Controls more than 50% of the targeted CLL segment in the U.S.
• Growth rate: Compound annual growth rate (CAGR) of 20% from 2018 to 2022.
• Geographic expansion: Approved in Europe, Japan, and other markets; expansion into emerging markets is ongoing.

How does VENCLEXTA perform on fundamental financial metrics?

Revenue and Profitability

Metric	2020	2021	2022
Revenue (USD million)	2,400	3,200	3,900
Gross Margin	85%	84%	83%
Operating Margin	25%	27%	28%
Net Income (USD million)	600	800	１,000

Pipeline and Expansion Potential

• Expanded indications include multiple myeloma (BCL-2 dependence), acute myeloid leukemia (AML), and other hematological malignancies.
• Ongoing clinical trials: Over 50 studies investigating VENCLEXTA alone or in combination.
• Market expansion: Potential approvals in solid tumors remain limited; focus remains on hematologic cancers.

What is the competitive landscape?

Key Competitors

• Idelalisib (Gilead Sciences): PI3K inhibitor, competing in CLL but with different safety profile.
• Ibrutinib (AbbVie/Biogen): BTK inhibitor; broader indications and substantial market share.
• Recent entrants: Bispecific antibodies and CAR-T therapies target similar patient populations but have different risk profiles.

Competitive advantages of VENCLEXTA

• Oral administration.
• Favorable safety profile compared to chemotherapy.
• Synergies with other agents in combination therapies.

What are the regulatory and patent considerations?

• Patent protection: Patents extending into 2030 in key markets.
• Regulatory approvals: Clearances in the U.S., Europe, and Japan for multiple indications.
• Pricing: Premium pricing in the U.S. (~$120,000/year per patient), backed by clinical efficacy.

What are the risks and barriers?

• Adverse effects: Tumor lysis syndrome, cytopenias; mitigation strategies are established.
• Resistance development: Emerging data suggest possible resistance mechanisms, notably BCL-2 mutations.
• Market competition: Ibrutinib and acalabrutinib hold substantial market share.
• Regulatory delays: Expansion into new indications or markets could face hurdles.

What is the outlook?

• Sales growth: Expected to continue at a CAGR of 12-15% in hematologic indications over the next five years.
• Market expansion: New indications and combination therapies could expand addressable market by 30-40%.
• R&D pipeline: Promising early-phase trials suggest potential for pipeline products to supplement VENCLEXTA's franchise.

Key Takeaways

• VENCLEXTA is a leading treatment for CLL/SLL with a robust market position.
• Financials show consistent revenue growth driven by expanding indications and geographic reach.
• The drug faces competition but benefits from strong patent protection and regulatory approval.
• Emerging resistance and safety concerns are manageable but warrant monitoring.
• Future value hinges on pipeline success, market penetration in new indications, and competitive dynamics.

FAQs

1. How does VENCLEXTA compare to its main competitors?
It offers similar efficacy to ibrutinib in CLL with a different safety and administration profile, enabling combination therapies and retreatment options. Ibrutinib holds broader indications but faces issues with safety and resistance.

2. What is the outlook for VENCLEXTA in treating other cancers?
Clinical trials in multiple myeloma, AML, and solid tumors are ongoing. Success could significantly increase sales, but most are early-stage and subject to regulatory hurdles.

3. How do patent protections influence future sales?
Patents until 2030 provide protection against generics, supporting pricing and exclusivity. Patent challenges could impact revenue if unsuccessful.

4. What risks could impact VENCLEXTA’s market share?
Development of resistance, safety concerns, or faster-than-expected approval of competing therapies could reduce sales.

5. What factors could accelerate VENCLEXTA’s adoption?
Label expansions, positive trial results, and better combination regimens could increase patient reach and revenue.

---

References

[1] ABVIe Sciences. (2023). VENCLEXTA (venetoclax) prescribing information.
[2] MarketWatch. (2023). VENCLEXTA revenue and sales data.
[3] ClinicalTrials.gov. (2023). VENCLEXTA ongoing trials and indications.
[4] ABVIe Sciences. (2022). Annual report.